ECSP077235A - Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa - Google Patents

Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa

Info

Publication number
ECSP077235A
ECSP077235A EC2007007235A ECSP077235A ECSP077235A EC SP077235 A ECSP077235 A EC SP077235A EC 2007007235 A EC2007007235 A EC 2007007235A EC SP077235 A ECSP077235 A EC SP077235A EC SP077235 A ECSP077235 A EC SP077235A
Authority
EC
Ecuador
Prior art keywords
compounds
trifluoro
methyl
benzamids
replaced
Prior art date
Application number
EC2007007235A
Other languages
English (en)
Spanish (es)
Inventor
Pascal Furet
Patricia Imbach
Georg Martiny-Baron
Giorgio Caravatti
Lawrence Blas Perez
Tao Sheng
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP077235A publication Critical patent/ECSP077235A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/74Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
EC2007007235A 2004-08-11 2007-02-09 Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa ECSP077235A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0417905.7A GB0417905D0 (en) 2004-08-11 2004-08-11 Organic compounds

Publications (1)

Publication Number Publication Date
ECSP077235A true ECSP077235A (es) 2007-03-29

Family

ID=33017336

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007235A ECSP077235A (es) 2004-08-11 2007-02-09 Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa

Country Status (17)

Country Link
US (2) US20080096883A1 (OSRAM)
EP (1) EP1778640A1 (OSRAM)
JP (1) JP2008509187A (OSRAM)
KR (1) KR20070046851A (OSRAM)
CN (2) CN101039914A (OSRAM)
AU (1) AU2005270313A1 (OSRAM)
BR (1) BRPI0514288A (OSRAM)
CA (1) CA2575316A1 (OSRAM)
EC (1) ECSP077235A (OSRAM)
GB (1) GB0417905D0 (OSRAM)
IL (1) IL181169A0 (OSRAM)
MA (1) MA28822B1 (OSRAM)
MX (1) MX2007001642A (OSRAM)
NO (1) NO20071300L (OSRAM)
RU (1) RU2007108861A (OSRAM)
TN (1) TNSN07048A1 (OSRAM)
WO (1) WO2006015859A1 (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
JP5079500B2 (ja) * 2005-04-28 2012-11-21 協和発酵キリン株式会社 2−アミノキナゾリン誘導体
AU2007234382B2 (en) * 2006-04-05 2011-06-09 Novartis Ag Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
BRPI0714307A2 (pt) * 2006-07-13 2014-06-10 Novartis Ag Uso de benzamidas trifluormetil-substituídas no tratamento de distúrbios neurológicos
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
WO2008009077A2 (en) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
ATE501124T1 (de) * 2006-09-05 2011-03-15 Amgen Inc Phthalazin-, aza- und diazaphthalazinverbindungen und anwendungsverfahren
EP2117544A4 (en) * 2006-12-19 2010-03-03 Univ Texas BIOMARKER FOR IDENTIFYING REACTIVATION FROM STAT3 TO SRC INHIBITION
EP2121692B1 (en) * 2006-12-22 2013-04-10 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
US8022085B2 (en) 2007-05-07 2011-09-20 Amgen Inc. Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof
CA2685674C (en) * 2007-05-07 2012-07-17 Amgen Inc. Pyrazolo-pyridinone compounds, process for their preparation, and their pharmaceutical use
US20100292292A1 (en) * 2007-09-13 2010-11-18 Link Medicine Corporation Treatment of Neurodegenerative Diseases Using Indatraline Analogs
WO2009117156A1 (en) * 2008-03-21 2009-09-24 Amgen Inc. Pyrazolo-pyrazinone compounds and methods of use thereof
EP2269993B1 (en) 2008-04-23 2013-02-27 Kyowa Hakko Kirin Co., Ltd. 2-aminoquinazoline derivative
US8420649B2 (en) 2008-08-29 2013-04-16 Amgen Inc. Pyrido[3,2-d]pyridazine-2(1H)-one compounds as p38 modulators and methods of use thereof
WO2010025201A1 (en) 2008-08-29 2010-03-04 Amgen Inc. Pyridazino- pyridinone compounds for the treatment of protein kinase mediated diseases.
US8772481B2 (en) 2008-10-10 2014-07-08 Amgen Inc. Aza- and diaza-phthalazine compounds as P38 map kinase modulators and methods of use thereof
WO2010042649A2 (en) 2008-10-10 2010-04-15 Amgen Inc. PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF
WO2010096395A1 (en) * 2009-02-18 2010-08-26 Syntech Solution Llc Amides as kinase inhibitors
JP2012529517A (ja) 2009-06-09 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー ベンジル置換トリアジン誘導体類及びそれらの治療応用
KR101457027B1 (ko) 2009-06-09 2014-10-31 캘리포니아 캐피탈 에쿼티, 엘엘씨 트리아진 유도체와 이들의 치료적 용도
CA2765053C (en) 2009-06-09 2015-08-18 California Capital Equity, Llc Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
JP2013509444A (ja) * 2009-10-30 2013-03-14 アリアド・ファーマシューティカルズ・インコーポレイテッド がんの治療方法及び治療用組成物
CN102675289B (zh) * 2011-03-18 2014-11-05 浙江大德药业集团有限公司 作为蛋白激酶抑制剂的n-苯基苯甲酰胺衍生物
WO2012148792A1 (en) * 2011-04-26 2012-11-01 Merck Sharp & Dohme Corp. Heterocyclic compounds as b-raf inhibitors for treatment of cancer
PL3321265T3 (pl) 2015-03-04 2020-11-16 Gilead Sciences, Inc. Związki 4,6-diamino-pirydo[3,2-d]pirymidynowe i ich wykorzystanie jako modulatorów receptorów toll-podobnych
EP3507288B1 (en) 2016-09-02 2020-08-26 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
CA3035346A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. Toll like receptor modulator compounds
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CN111904960A (zh) * 2020-05-19 2020-11-10 合肥合源药业有限公司 一种固体分散体及药用组合物
KR102463217B1 (ko) * 2020-07-13 2022-11-07 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 4-아미노퀴나졸린-2-카복스아미드 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
CN111925331A (zh) * 2020-07-14 2020-11-13 上海毕得医药科技有限公司 一种6-溴酞嗪的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6587829B1 (en) * 1997-07-31 2003-07-01 Schering Corporation Method and apparatus for improving patient compliance with prescriptions
US6523009B1 (en) * 1999-11-06 2003-02-18 Bobbi L. Wilkins Individualized patient electronic medical records system
US20030236682A1 (en) * 1999-11-08 2003-12-25 Heyer Charlette L. Method and system for managing a healthcare network
US6684276B2 (en) * 2001-03-28 2004-01-27 Thomas M. Walker Patient encounter electronic medical record system, method, and computer product
GB0217757D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use

Also Published As

Publication number Publication date
TNSN07048A1 (en) 2008-06-02
WO2006015859A1 (en) 2006-02-16
RU2007108861A (ru) 2008-09-20
CN101039914A (zh) 2007-09-19
CA2575316A1 (en) 2006-02-16
JP2008509187A (ja) 2008-03-27
US20060035897A1 (en) 2006-02-16
MA28822B1 (fr) 2007-08-01
GB0417905D0 (en) 2004-09-15
IL181169A0 (en) 2007-07-04
NO20071300L (no) 2007-04-19
KR20070046851A (ko) 2007-05-03
AU2005270313A1 (en) 2006-02-16
EP1778640A1 (en) 2007-05-02
MX2007001642A (es) 2007-04-10
BRPI0514288A (pt) 2008-06-10
US20080096883A1 (en) 2008-04-24
CN101696188A (zh) 2010-04-21

Similar Documents

Publication Publication Date Title
ECSP077235A (es) Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa
UY30779A1 (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
CR10072A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
CR20110608A (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
DOP2010000013A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CR11614A (es) Pirrolo[2,3-d]piridinas y usos de las mismas como inhibidores de cinasa de tirosina
CR11201A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
DOP2010000012A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
ECSP088821A (es) Derivados de tioxantina y su uso como inhibidores de la mpo
CL2021000514A1 (es) Dimetilaminoazetidinaminas como inhibidores de jak
CR8778A (es) Revestimientos de azucar y metodos para estos
UY32190A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibdores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales
CO6630193A2 (es) Inhibidores de la actividad de la proteína tirosina quinasa seleccionada
UY32829A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone
UY28993A1 (es) Tetrahidroisoquinolinas sustituidas en calidad de inhibidores de mpm, procedimiento para su uso como medicamento.-
UY28460A1 (es) Compuestos de aminotriazol útiles como inhibidores de quinasas de proteinas
CU23596A3 (es) Derivados de pirazol-quinazolina y proceso para su preparación